samedan logo

 
 
spacer
home > white papers > Accelerating the Time from DNA to Material - Merck
WHITE PAPERS
logo_Merck.jpg

Merck

phone +33 (0)5 57 960 960
email Sebastien.ribault@merckgroup.com
web http://www.merckmillipore.com/adaptive-CDMO
email 1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

Accelerating the Time from DNA to Material

Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
Accelerating the Time from DNA to Material
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Sanofi, Capgemini, Generali and Orange announce the creation of a digital ecosystem dedicated to e-health, a first in Europe

Sanofi, Capgemini, Generali and Orange announce plans to create a joint venture in France to fast-track the development of concrete healthcare solutions and to make them available to the market for the benefit of patients. The project, on a scale that is unique in Europe, will bring together leading scientific and technological expertise in France and Europe. It will benefit from both a virtual platform and a physical base located in Paris, linked to the « PariSanté Campus » initiative announced by the French President and will strengthen the international positioning of France in digital health.
More info >>


White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>


Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement